E Fund Management Co. Ltd. Trims Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)

E Fund Management Co. Ltd. decreased its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 20.6% during the fourth quarter, Holdings Channel.com reports. The fund owned 21,425 shares of the company’s stock after selling 5,557 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Vir Biotechnology were worth $216,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of VIR. China Universal Asset Management Co. Ltd. raised its position in shares of Vir Biotechnology by 96.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,448 shares of the company’s stock valued at $32,000 after purchasing an additional 1,692 shares during the period. Signaturefd LLC boosted its holdings in Vir Biotechnology by 258.5% in the 4th quarter. Signaturefd LLC now owns 3,327 shares of the company’s stock worth $33,000 after buying an additional 2,399 shares during the period. Fifth Third Bancorp increased its stake in Vir Biotechnology by 69.3% in the 3rd quarter. Fifth Third Bancorp now owns 3,941 shares of the company’s stock worth $37,000 after buying an additional 1,613 shares in the last quarter. Federated Hermes Inc. bought a new stake in Vir Biotechnology during the fourth quarter valued at about $69,000. Finally, PNC Financial Services Group Inc. lifted its position in shares of Vir Biotechnology by 99.9% in the third quarter. PNC Financial Services Group Inc. now owns 9,317 shares of the company’s stock valued at $87,000 after acquiring an additional 4,656 shares in the last quarter. 65.32% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on VIR shares. Needham & Company LLC reiterated a “buy” rating and set a $15.00 target price on shares of Vir Biotechnology in a research report on Friday, May 3rd. HC Wainwright reaffirmed a “buy” rating and set a $110.00 price objective on shares of Vir Biotechnology in a report on Tuesday. Finally, JPMorgan Chase & Co. boosted their target price on shares of Vir Biotechnology from $10.00 to $12.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Vir Biotechnology has a consensus rating of “Moderate Buy” and a consensus price target of $33.57.

Insiders Place Their Bets

In other Vir Biotechnology news, EVP Phillip Pang sold 3,321 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $10.24, for a total value of $34,007.04. Following the completion of the sale, the executive vice president now directly owns 264,679 shares in the company, valued at approximately $2,710,312.96. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, EVP Ann M. Hanly sold 12,296 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $10.05, for a total value of $123,574.80. Following the sale, the executive vice president now owns 134,780 shares of the company’s stock, valued at $1,354,539. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Phillip Pang sold 3,321 shares of the firm’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $10.24, for a total value of $34,007.04. Following the completion of the sale, the executive vice president now owns 264,679 shares in the company, valued at $2,710,312.96. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 152,831 shares of company stock worth $1,525,844. Company insiders own 15.60% of the company’s stock.

Vir Biotechnology Trading Up 0.2 %

Shares of Vir Biotechnology stock opened at $9.56 on Friday. The firm’s 50 day simple moving average is $9.66 and its two-hundred day simple moving average is $9.64. Vir Biotechnology, Inc. has a 12-month low of $7.61 and a 12-month high of $27.48. The firm has a market capitalization of $1.29 billion, a price-to-earnings ratio of -2.38 and a beta of 0.47.

Vir Biotechnology (NASDAQ:VIR) last issued its earnings results on Thursday, May 2nd. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.51. Vir Biotechnology had a negative return on equity of 32.58% and a negative net margin of 677.69%. The firm had revenue of $56.38 million for the quarter, compared to the consensus estimate of $11.71 million. During the same quarter in the prior year, the business earned ($1.06) earnings per share. The company’s revenue was down 10.5% compared to the same quarter last year. On average, sell-side analysts predict that Vir Biotechnology, Inc. will post -4.04 EPS for the current fiscal year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.